Copyright 2024 All rights reserved.

What We Do

By overcoming barriers that seemed impossible, we have established platform

technologies for development of pharmaceuticals that anyone can safely use regardless of time and place.

What We Do

Extracellular Vesicle Therapeutics

What is Extracellular Vesicles (EVs) ?

Extracellular vesicles (EVs) are nano-sized particles limited by lipid bilayers that are released from most cells. EVs perform various biological functions such as repair and regeneration of damaged tissues, generation of new blood vessels, regulation of immune responses, and maintenance of homeostasis by delivering various substances such as proteins, mRNAs, and miRNAs contained inside to other cells or tissues. EVs are mainly used for diagnosis of diseases (especially cancer cell-derived EVs), treatment of diseases, and delivery of drugs for treatment. In particular, stem cell-derived EVs are receiving a lot of attention as candidates for next-generation advanced biopharmaceuticals that can replace stem cell treatments.

Application of Extracellular Vesicles
According to Cell Origin
Cancer Cell
  • Establishing tumor

    microenvironment (TME)
  • Promoting cancer metastasis
for Diagnosis
Immune Cells
  • Delivering antigenic peptides
  • Regulating immune responses
Cancer Cell
  • Restore damaged cell/tissue
  • Cell proliferation/differentiation
for Treatment /

Drug delivery
Function of extracellular vesicles derived from stem cells
Alternative to
Stem Cell Therapy
  • Regenerative treatment

    for skin, muscle, bone,
    cartilage, blood vessel,

    lung, kidney, heart, etc
  • Neurodegenerative disease

    treatment     including
    Alzheimer’s, Parkinson’s

    disease, etc
  • Autoimmune disease

    treatment
    for

    Atopy, asthma,

    Crohn’s disease, etc
  • Anti-tumor

    treatment
  • Infectious disease

    prevention & treatment
    including COVID-19
R&D Status of
extracellular vesicle
therapeutics by diseases
(Clinical trials in progress)

Immune Rejection of EVs by mismatching MHC

Like cells, since EVs express antigenic molecules (MHC) in the lipid bilayer membrane, immune rejection by MHC-mismatching may occur when allogeneic EVs are administered. Furthermore, the proliferation of T cells is activated by the administered allogeneic EVs, which may cause undesired immune or allergic reactions. To reduce the risk of immune response by allogeneic EV therapeutics, it is recommended to match HLA-typing between donors and patients or to use immunosuppressive agents.


(Report on therapeutic preparations using extracellular vesicles (EV) including exosomes, 2023, PMDA, Japan)
Immune Rejection of allogeneic Extracellular Vesicles
Caused by Mismatching
Major Histocompatibility
Complex (MHC)

  • Cellular Uptake of
    injected EVs by Phagocytosis
    (macrophage and monocyte)

    (Traffic. 2010, 11, 675)

  • Half-life of injected EVs in blood is
    about 2 mins and found
    only in Lung and Spleen after 4 hr

    (Int. J. Mol. Sci. 2017, 18, 1249)

  • Injected EVs activate
    T cell proliferation(immune response)
    in concentration-dependent manner

    (J. Clin. Invest. 2016, 126, 2805)
MBTC-EVs
World-first HLA-G+ Extracellular Vesicles Therapeutics without Immunogenicity
Ready-made EV therapeutics
safe for allogeneic application
Item HLA-G+ MBTC-EVs HLA-G- EVs
(from ESCs, iPSCs, MSCs, HSCs)
Expression of HLA-A/B/C Yes Yes
Expression and Secretion of HLA-G Yes No
Immunogenicity No Yes
Possible for allogeneic use Yes No
Need to match HLA-typing No Yes
Need to use immunosuppressant No Yes